Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways.
Adv Ther
; 38(3): 1397-1403, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-1085619
ABSTRACT
The availability of pangenotypic direct-acting antivirals for treatment of hepatitis C (HCV) has provided an opportunity to simplify patient pathways. Recent clinical practice guidelines have recognised the need for simplification to ensure that elimination of HCV as a public health concern remains a priority. Despite the move towards simplified treatment algorithms, there remains some complexity in the recommendations for the management of genotype 3 patients with compensated cirrhosis. In an era where additional clinical trial data are not anticipated, clinical guidance should consider experience gained in real-world settings. Although more experience is required for some pangenotypic therapeutic options, on the basis of published real-world data, there is already sufficient evidence to consider a simplified approach for genotype 3 patients with compensated cirrhosis. The coronavirus disease 2019 (COVID-19) pandemic has highlighted the need to minimise the need for complex patient pathways and clinical practice guidelines need to continue to evolve in order to ensure that patient outcomes remain optimised.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Communicable Disease Control
/
Hepatitis C
/
Critical Pathways
/
Disease Eradication
/
COVID-19
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Adv Ther
Journal subject:
Therapeutics
Year:
2021
Document Type:
Article
Affiliation country:
S12325-021-01636-7
Similar
MEDLINE
...
LILACS
LIS